Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TELO
Strong SellSinkerTelomir Pharmaceuticals, Inc. · Healthcare · United States · $78M · Avg Vol: $65K/d
15
StockRankGet insider-trade alerts
Q
31
V
24
M
39
P/E (TTM)
—
ROE
-213.1%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -0.01 | -0.19 | -0.24 | -0.16 | — | -1.16 |
| Shares | 68.8M | 68.8M | 68.8M | 68.8M | 0.0% | 68.8M |
| Debt | — | 0.1M | — | — | — | 0.1M |
| Equity | -0.9M | 3.4M | 0.6M | 5.9M | 31.1% | — |
| Op CF | -0.5M | -3.9M | -5.1M | -3.7M | — | -4.9M |
| Inv CF | — | — | — | — | — | — |
| Fin CF | 0.5M | 3.9M | 6.3M | 9.7M | — | — |
Loading 1Y...
PRICE (1Y)+0.8%
SMA 50SMA 200
Close
$1.22
RSI (14)
57.6
52W High
$2.09
From 52W High
0.6%
SCORE BREAKDOWN
Quality
31
ROIC
-156.0%3.9
ROE
-213.1%4.1
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-20.4%20.7
Piotroski
457.9
Int. Cover
-50.0x5.9
D/E Ratio
0.03x77.2
Current Ratio
16.14x94.0
Value
24
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
8.1x15.7
P/S
—N/A
Div Yield
—N/A
Momentum
39
52W High %
58%32.9
RS 6M
-19%41.0
SMA 50/200
0.92x36.3
EPS Rev 4W
0.0%34.5
EPS Rev 12W
—N/A
EPS Improve
+76%67.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$78M
P/E (Forward)
-4.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TELO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals, Inc.(you) | $78M | 15 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 14 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| MAIA | MAIA Biotechnology, Inc. | $81M | 12 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 17 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 16 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 13 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%